| Drug NDC: | 62185-0055 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Intercellular Detox |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Ceanothus Americanus, Argentum Nitricum, Condurango, Hydrastis Canadensis, Momordica Balsamina, Pulsatilla (pratensis), Bile Duct (suis), Colon (suis), Duodenum (suis), Esophagus (suis), Eye (suis), Gallbladder (suis), Ileum (suis), Intestine (suis), Ipecacuanha, Jejunum (suis), Kali Bichromicum, Lung (suis), Mucosa Nasalis Suis, Natrum Oxalaceticum, Oral Mucosa (suis), Pancreas Suis, Phosphorus, Rectal Mucosa (suis), Stomach (suis), Sulphur, Veratrum Album, Mannose, Anacardium Orientale, Kreosotum, |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Dr. Donna Restivo Dc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ANEMONE PRATENSIS - 6 [hp_X]/mL CEANOTHUS AMERICANUS LEAF - 4 [hp_X]/mL GOLDENSEAL - 6 [hp_X]/mL IPECAC - 8 [hp_X]/mL LACHESIS MUTA VENOM - 10 [hp_X]/mL MANDRAGORA OFFICINARUM ROOT - 16 [hp_X]/mL MANNOSE, D- - 8 [hp_X]/mL MARSDENIA CONDURANGO BARK - 6 [hp_X]/mL MOMORDICA BALSAMINA IMMATURE FRUIT - 6 [hp_X]/mL OXALIS ACETOSELLA LEAF - 10 [hp_X]/mL Load more... PHOSPHORUS - 8 [hp_X]/mL PORK INTESTINE - 8 [hp_X]/mL POTASSIUM DICHROMATE - 8 [hp_X]/mL SEMECARPUS ANACARDIUM JUICE - 9 [hp_X]/mL SHIGELLA DYSENTERIAE - 30 [hp_C]/mL SILVER NITRATE - 6 [hp_X]/mL SODIUM DIETHYL OXALACETATE - 8 [hp_X]/mL SULFUR - 8 [hp_X]/mL SUS SCROFA BILE DUCT - 8 [hp_X]/mL SUS SCROFA COLON - 8 [hp_X]/mL SUS SCROFA DUODENUM - 8 [hp_X]/mL SUS SCROFA ESOPHAGUS - 8 [hp_X]/mL SUS SCROFA EYE - 8 [hp_X]/mL SUS SCROFA GALLBLADDER - 8 [hp_X]/mL SUS SCROFA ILEUM - 8 [hp_X]/mL SUS SCROFA JEJUNUM - 8 [hp_X]/mL SUS SCROFA LUNG - 8 [hp_X]/mL SUS SCROFA NASAL MUCOSA - 8 [hp_X]/mL SUS SCROFA ORAL MUCOSA - 8 [hp_X]/mL SUS SCROFA PANCREAS - 8 [hp_X]/mL SUS SCROFA RECTAL MUCOSA - 8 [hp_X]/mL SUS SCROFA STOMACH - 8 [hp_X]/mL SUS SCROFA URINARY BLADDER - 6 [hp_C]/mL VERATRUM ALBUM ROOT - 8 [hp_X]/mL WOOD CREOSOTE - 10 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 19 Feb, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 23 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Dr. Donna Restivo DC |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| UNII: | 8E272251DI 25B1Y14T8N ZW3Z11D0JV 62I3C8233L VSW71SS07I I2XCB174VB PHA4727WTP R23QIR6YBA WUW1665V10 U1W3U02EW0 Load more... 27YLU75U4W 40GMI0R60L T4423S18FM Y0F0BU8RDU 1EP6R5562J 95IT3W8JZE 6CA025Y4FG 70FD1KFU70 4EE983392U 94J255A0UC P6J2SFT80O 81FZ7X4MWD X3AOK514E6 B6A98VOI9I C998R1XSRA TA501QD69R 7GL3G1COB3 ID3Z1X61WY DUP6W562BM 9Y3J3362RY 03T60V100Y T0920P9Z9A 3G7U72W8DA QNS6W5US1Z 3JYG22FD73 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 62185-0055-1 | 30 mL in 1 BOTTLE, DROPPER (62185-0055-1) | 19 Feb, 2020 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.